Read More

What’s Happening With Eli Lilly Shares On Monday?

Eli Lilly reports detailed results from the SYNERGY-NASH phase 2 study. The trial, involving 190 patients with and without type 2 diabetes, showed tirzepatide met the primary endpoint, achieving MASH resolution without fibrosis worsening. Participants taking 5 mg, 10 mg, and 15 mg doses saw significant improvements compared to placebo, presented at the EASL Congress 2024.

LLY